Use of low-dose topiramate in substance use disorder and bodyweight control

Yi Hang Chiu, Ting Hui Lee, Winston W. Shen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In recent years topiramate has been used for psychiatric patients, mainly for controlling substance use and food intake. A total of 46 patients who received topiramate treatment during the study period were identified from a computer database. Nineteen had received topiramate for at least 1 month. Twelve patients received topiramate for anticraving effects (alcohol, n = 9; heroin/amphetamine, n = 1; meperidine, n = 1; and nicotine, n = 1). On an average dosage of 112.5 mg/day, nine of the 12 patients (excluding three alcoholic patients) achieved complete or partial remission from the substance use disorders. The present results show that six of the nine patients achieved full or partial remission from alcohol use disorder on a dosage of 100 mg/day. Topiramate was also used to control seven patients' bodyweight (mean bodyweight change, 1.53 kg). Four of them achieved bodyweight loss in the 1-month follow up, with an average change of 2.65 kg. Based on the present findings topiramate

Original languageEnglish
Pages (from-to)630-633
Number of pages4
JournalPsychiatry and Clinical Neurosciences
Volume61
Issue number6
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Substance-Related Disorders
Alcohols
Meperidine
Heroin
Amphetamine
Alcoholics
topiramate
Nicotine
Psychiatry
Eating
Databases

Keywords

  • Alcohol dependence
  • Bodyweight
  • Substance dependence
  • Substance use disorder
  • Topiramate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Use of low-dose topiramate in substance use disorder and bodyweight control. / Chiu, Yi Hang; Lee, Ting Hui; Shen, Winston W.

In: Psychiatry and Clinical Neurosciences, Vol. 61, No. 6, 12.2007, p. 630-633.

Research output: Contribution to journalArticle

@article{79328f116a074cf1a0181ffa62cf6e5c,
title = "Use of low-dose topiramate in substance use disorder and bodyweight control",
abstract = "In recent years topiramate has been used for psychiatric patients, mainly for controlling substance use and food intake. A total of 46 patients who received topiramate treatment during the study period were identified from a computer database. Nineteen had received topiramate for at least 1 month. Twelve patients received topiramate for anticraving effects (alcohol, n = 9; heroin/amphetamine, n = 1; meperidine, n = 1; and nicotine, n = 1). On an average dosage of 112.5 mg/day, nine of the 12 patients (excluding three alcoholic patients) achieved complete or partial remission from the substance use disorders. The present results show that six of the nine patients achieved full or partial remission from alcohol use disorder on a dosage of 100 mg/day. Topiramate was also used to control seven patients' bodyweight (mean bodyweight change, 1.53 kg). Four of them achieved bodyweight loss in the 1-month follow up, with an average change of 2.65 kg. Based on the present findings topiramate",
keywords = "Alcohol dependence, Bodyweight, Substance dependence, Substance use disorder, Topiramate",
author = "Chiu, {Yi Hang} and Lee, {Ting Hui} and Shen, {Winston W.}",
year = "2007",
month = "12",
doi = "10.1111/j.1440-1819.2007.01718.x",
language = "English",
volume = "61",
pages = "630--633",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Use of low-dose topiramate in substance use disorder and bodyweight control

AU - Chiu, Yi Hang

AU - Lee, Ting Hui

AU - Shen, Winston W.

PY - 2007/12

Y1 - 2007/12

N2 - In recent years topiramate has been used for psychiatric patients, mainly for controlling substance use and food intake. A total of 46 patients who received topiramate treatment during the study period were identified from a computer database. Nineteen had received topiramate for at least 1 month. Twelve patients received topiramate for anticraving effects (alcohol, n = 9; heroin/amphetamine, n = 1; meperidine, n = 1; and nicotine, n = 1). On an average dosage of 112.5 mg/day, nine of the 12 patients (excluding three alcoholic patients) achieved complete or partial remission from the substance use disorders. The present results show that six of the nine patients achieved full or partial remission from alcohol use disorder on a dosage of 100 mg/day. Topiramate was also used to control seven patients' bodyweight (mean bodyweight change, 1.53 kg). Four of them achieved bodyweight loss in the 1-month follow up, with an average change of 2.65 kg. Based on the present findings topiramate

AB - In recent years topiramate has been used for psychiatric patients, mainly for controlling substance use and food intake. A total of 46 patients who received topiramate treatment during the study period were identified from a computer database. Nineteen had received topiramate for at least 1 month. Twelve patients received topiramate for anticraving effects (alcohol, n = 9; heroin/amphetamine, n = 1; meperidine, n = 1; and nicotine, n = 1). On an average dosage of 112.5 mg/day, nine of the 12 patients (excluding three alcoholic patients) achieved complete or partial remission from the substance use disorders. The present results show that six of the nine patients achieved full or partial remission from alcohol use disorder on a dosage of 100 mg/day. Topiramate was also used to control seven patients' bodyweight (mean bodyweight change, 1.53 kg). Four of them achieved bodyweight loss in the 1-month follow up, with an average change of 2.65 kg. Based on the present findings topiramate

KW - Alcohol dependence

KW - Bodyweight

KW - Substance dependence

KW - Substance use disorder

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=36849030836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849030836&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.2007.01718.x

DO - 10.1111/j.1440-1819.2007.01718.x

M3 - Article

C2 - 18081623

AN - SCOPUS:36849030836

VL - 61

SP - 630

EP - 633

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 6

ER -